A pioneering study has found that an individualized approach to breast cancer screening that assesses patients’ risk, rather than annual mammograms, can lower the chance of more advanced cancers, while still safely match people to the amount of screening they need.
Seven investigators have been awarded grants this fall for research on factors driving differences in health outcomes in meningioma, prostate cancer, and breast cancer.
Hematologists and oncologists from UCSF will share research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology – the American Society of Hematology’s (ASH) 67th Annual Meeting and Exposition. This year’s meeting will be held in Orlando, Dec. 6-9.
NIH-funded discoveries by UCSF's Kevan Shokat, PhD have produced the world’s first drugs that target mutations in the KRAS gene which cause a quarter of all cancerous tumors.
Our Global Cancer Program joined international collaborators at the African Organisation for Research and Training in Cancer (AORTIC) conference in Tunisia.
He was told cancer would kill him in two to four years. Fourteen years later, he credits a series of medications and treatments funded by the National Institutes of Health.
Matching grant from Weill family creates collaborative research hub, uniting scientists from UCSF and Stanford Medicine to transform cancer care within a decade.